打造心血管赛道的“中国样本”！北芯生命成功登陆科创板

Core Viewpoint - North Chip Life has successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, marking a significant milestone as the first medical device company to do so under the new fifth set of standards, with an opening price that surged 187% from the issue price [2][4]. Group 1: Company Overview - North Chip Life is recognized as a "hexagonal warrior" in the medical device industry, demonstrating balanced development across product innovation, global market entry, commercialization, and profitability [4][12]. - The company focuses on innovative and high-quality cardiovascular precision intervention solutions, aiming to fill the technological gaps in China's medical device industry [5][6]. Group 2: Investment and Support - Sequoia China has been a key investor since 2018, providing continuous support in strategic choices, operational advice, and international promotion [5][6][9]. - The investment team at Sequoia China identified the potential in North Chip Life's technology, leading to significant funding and strategic guidance throughout the company's growth [9][10]. Group 3: Product Innovation - North Chip Life has developed the first domestically approved 60MHz high-speed IVUS product and a domestic FFR measurement system, showcasing the capability of Chinese companies to redefine market standards through technological advancements [6][12]. - The company emphasizes differentiated innovation in its product development, addressing clinical pain points rather than merely replicating existing products [12][13]. Group 4: Market Expansion - North Chip Life has established strategic partnerships to enhance its overseas market presence, with international sales contributing over 15% of its revenue as of September 30, 2025 [10]. - The company is actively expanding its product offerings in the cardiovascular diagnosis and treatment sectors, focusing on high-performance and high-barrier medical devices [12][13].